Introduction
Supplemental oxygen therapy has been a cornerstone of supportive care in ST-elevation myocardial infarction (STEMI) for more than a century and is widely endorsed by international guidelines. 1, 2 Oxygen is considered to increase oxygen supply to the ischaemic myocardium and thereby improve cardiac metabolism, reduce infarct size, prevent circulatory chock, and ultimately, improve patient outcomes. Small clinical trials indicated positive results on surrogate endpoints, [3] [4] [5] but no trial so far has been large enough to evaluate hard clinical endpoints. On the contrary, data from a recent clinical trial 6 and experimental studies have demonstrated negative effects of oxygen therapy on cardio-circulatory haemodynamics due to direct hyperoxaemic vasoconstriction and increased production of reactive oxygen species. 7, 8 A dose-dependent relationship between oxygen exposure and risk for myocardial injury has been proposed. 9 In the setting of STEMI and acute primary percutaneous coronary intervention (PCI), reopening of the occluded vessel is closely associated with reperfusion injury, which can lead to arrhythmias, contractile dysfunction, microvascular impairment, and irreversible myocardial damage, 10 all enhanced by reactive oxygen species. 11 Further, vasoconstriction may lead to underestimation of the diameter of the culprit coronary artery and undersizing of the coronary stent with successive long-term risk of stent thrombosis, restenosis, and need for target vessel revascularization. 12, 13 The DETermination of the role of Oxygen in suspected Acute Myocardial Infarction (DETO2X-AMI) trial randomized patients with suspected myocardial infarction (MI) to receive oxygen at 6 L/min for 6-12 h or ambient air. The primary endpoint of all-cause death at 1 year as well as secondary endpoints of rehospitalization with MI and cardiac troponin T levels did not show any significant difference between the two study groups. 14 If routine oxygen therapy affects hard clinical endpoints or procedure-related outcomes in STEMI patients undergoing PCI remains uncertain. 6, 15, 16 In this pre-specified subgroup analysis, we therefore aimed to evaluate whether supplemental oxygen reduces major adverse cardiac events and procedure-related clinical outcomes at 1 year in STEMI patients undergoing PCI.
Methods

Study design
The DETO2X-AMI trial was a nationwide, multicentre, open-label, registry-based randomized clinical trial (RRCT) comparing routine supplemental oxygen therapy to ambient air in patients with suspected AMI. The study used the Swedish Web System for Enhancement and Development of Evidence-based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART) 17 registry for patient recruitment and trial procedures and follow-up. The trial design, 18 methods, and first results have been described in detail previously. 14 The ethics committee and the medical products agency of Sweden approved the study. Trial sponsor was Karolinska Institutet, Stockholm, Sweden. Uppsala Clinical Research Center at Uppsala University, Sweden, was responsible for trial administration, data management, and statistical analyses and is running the SWEDEHEART registry.
The study was designed and conducted, and the manuscript written, by the authors who vouch for the data and all analyses, and for the fidelity of this report to the trial protocol and statistical analysis plan which are available with the full text of this article online. The funding agencies had no access to the study data and no role in trial design, implementation, or reporting.
Patient population
Patients presenting to the ambulance service, emergency department, coronary care unit, or catheterization laboratory of participating hospitals were evaluated for enrolment. Trial participants were required to be 30 years of age or older and to have symptoms suggestive of AMI (defined as chest pain or shortness of breath) for <6 h, oxygen saturation of > _90% on pulse oximetry, and either electrocardiogram (ECG) changes indicating ischaemia 13 or elevated cardiac troponin on admission (above the locally defined decision limit for MI). To allow complete follow-up through the Swedish National Population Registry, only Swedish citizens with a unique personal identification number were enrolled. Patients with ongoing oxygen therapy or cardiac arrest prior to enrolment were excluded. If supplemental oxygen therapy had been administered for <20 min before evaluation for enrolment, a new evaluation was allowed after discontinuation of oxygen delivery and 10 min of washout.
For this analysis, only patients with discharge diagnosis STEMI with performed PCI were evaluated, all others excluded.
Study procedures
After providing initial oral consent, patients who fulfilled all inclusion criteria and had no exclusion criteria were randomly assigned, in a 1:1 ratio, to either oxygen therapy at 6 L/min for 6-12 h delivered by open face mask or ambient air. Randomization was performed by means of an online randomization module following a computer-generated list within the SWEDEHEART database. The study treatment was initiated directly on site immediately after randomization.
All patients were asked to confirm their agreement to participate by providing written informed consent within 24 h. All patients were treated according to standard of care. Oxygen saturation was documented at the beginning and the end of the randomized treatment period. If clinically indicated, particularly in cases of hypoxaemia (defined as oxygen saturation below 90%) of any cause, patients received supplemental oxygen outside the protocol, which was reported separately.
Endpoints and definitions
Data on clinical outcomes and follow-up were obtained from SWEDEHEART and national health registries. Detailed procedural and outcome data were obtained from the national comprehensive Swedish Coronary Angiography and Angioplasty Registry (SCAAR) a part of SWEDEHEART. The present analysis regards the first major subgroup of the DETO2X trial. For this study, the pre-specified primary endpoint was a composite of all-cause death, rehospitalization with MI, cardiogenic shock, or stent thrombosis at 1 year [major adverse cardiac event (MACE1)]. The secondary endpoint was a composite of MACE1 and target vessel revascularization (MACE2). The primary objective was also analysed in relevant subgroups and at different points in time such as during hospital stay, at 30 days and the total follow-up time.
We included patients who underwent PCI and had a final STEMI diagnosis in SWEDEHEART defined according to International Classification of Diseases 10th revision (ICD-10) code I. 21 Plus-minus values are mean ± SD. There were no significant differences in baseline characteristics between oxygen group and the ambient-air group except as otherwise noted.
-denotes oxygen saturation at presentation is not registered in SWEDEHEART. ACE, angiotensin converting enzyme; AT, angiotensin; CABG, coronary artery bypass graft; CV, cardiovascular; DETO2X-STEMI, DETermination of the role of OXygen in Stsegment Elevated Myocardial Infarction; ECG, electrocardiogram; IQR, interquartile range; PCI, percutaneous coronary intervention.
a
The body-mass index (the weight in kilograms divided by the square of the height in meters). The local study team on site and steering committee were blinded to treatment comparisons until locking of the database, by restricting access to the randomization list to authorized SWEDEHEART registry personnel. Accumulated data without treatment group information were available for monitoring of study progress throughout the trial.
Statistical analysis
The sample-size calculations for the overall trial have been described previously. 18 There was no pre-specified power calculation for the present subgroup. Plus-minus values are mean ± SD. There were no significant differences in trial procedural data, medication, procedures and complications during the hospitalization period; or discharge diagnoses between the patients assigned to oxygen or the patients assigned to ambient air except as otherwise noted. -denotes in-hospital oxygen saturation is not registered in SWEDEHEART. AV, atrioventricular; IQR, interquartile range; PCI, percutaneous coronary intervention; x, not applicable. The results were analysed according to the intention-to-treat principle. Time to event within 365 days and the entire follow-up with a maximum of 1357 days (median duration 752 days) post-randomization is presented in the Kaplan-Meier curves. Hazard ratios (HRs) between treatment groups were calculated using a Cox proportional hazard model, adjusted for age in years (as a linear covariate on the log-hazard scale) and sex. Estimates of treatment differences are presented with two-tailed 95% confidence intervals (95% CI) and associated P-values. A two-tailed P-value of <0.05 was considered statistically significant. Eleven pre-specified subgroup analyses were performed using proportional hazards models with age and sex adjustment and formal tests for interaction.
All analyses were conducted with SAS v.9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Study population
Of the 6629 patients enrolled in the main trial, 2807 (42%) had a discharge diagnosis of STEMI with primary PCI performed and were included in this analysis. In all, 78% of these patients arrived by ambulance to the hospital, 61% were admitted directly to the coronary care unit or catheterization laboratory, and the remaining 17% through the emergency department. Overall, 2722 (97%) patients were enrolled due to chest pain and 27 (1%) due to shortness of breath as the qualifying symptom. 
Procedural data
At the time of randomization, the median oxygen saturation was 97.0% [interquartile range (IQR) 95.0-98.0%] in both groups. All randomized patients were followed according to the intention-totreat principle, 1361 allocated to oxygen which was initiated immediately after randomization, 1446 allocated to ambient air. The duration from symptom onset and diagnostic ECG to randomization, the duration from symptom onset and diagnostic ECG to PCI, and the duration from randomization to PCI was similar between the two groups. The median duration of oxygen therapy was 10.36 (IQR 6.02-12.00) h with a median oxygen saturation of 99.0% (IQR 97.0-100%) in patients assigned to oxygen and 97.0% (IQR 95.0-98.0%) in Figure 1 Enrolment, randomization, and follow-up. Eligible patients were evaluated for inclusion. Shown are the numbers of patients who were enrolled in the main study, randomly assigned to a study group, kept in this ST-elevation myocardial infarction sub group analysis and followed up during the study period; as well as ST-elevation myocardial infarction patients at participating sites not randomized during the trial period. AMI, acute myocardial infarction; DETO2X-AMI, DETermination of the role of Oxygen in Acute Myocardial Infarction; ITT, intention-to-treat; STEMI, ST-elevation myocardial infarction.
Oxygen therapy in STEMI Figure 2 The Kaplan-Meier curves for the composite of all-cause death, rehospitalization with myocardial infarction, cardiogenic shock, or stent thrombosis (major adverse cardiac event 1) up to 365 days. The Kaplan-Meier curves are shown for the cumulative probability of major adverse cardiac event 1 up to 365 days after randomization for patients assigned to oxygen or ambient air. The insets show the same data on an enlarged y-axis. MACE 1, major adverse cardiac event 1. patients assigned to ambient air at the end of the treatment period. Hypoxaemia occurred in 236 patients (8.4%) in total, 44 (3.2%) in the patients assigned to oxygen, 192 (13.3%) in the patients assigned to ambient air. In total, 122 (4.3%) patients did not complete the allocated treatment period, 86 (6.3%) patients allocated to oxygen, and 36 (2.5%) allocated to ambient air. Reasons for not fulfilling randomized therapy were as follows (oxygen/ambient air): withdrawal 4.1%/0.3%; early discharge (0%/0.3%); change of clinical circumstances 0.9%/0.4%; mistakes (technical, communication) 1.0%/1.3% (Figure 1) .
Baseline characteristics and clinical presentation for all randomized and non-randomized STEMI patients at participating sites during the trial period are listed in Table 1 . In-hospital procedural characteristics and complications are listed in Table 2 . Endpoints are summarized in Table 3 .
Clinical endpoints
The incidence of the composite of all-cause death, rehospitalization with MI, cardiogenic shock, or stent thrombosis at 1 year (MACE1) was 6.3% (86 of 1361) in the patients allocated to oxygen compared to 7.5% (108 of 1446) patients allocated to ambient air (HR 0.85, 95% CI 0.64-1.13; P = 0.27) (Figure 2 and Table 3 ). No significant interaction between the duration of therapy and the randomized groups on the primary endpoint was found (P = 0.22).
The incidence of the composite of all-cause death, rehospitalization with MI, cardiogenic shock, stent thrombosis, or target vessel revascularization at 1 year (MACE2) was 9.6% (130 of 1361) in the patients allocated to oxygen compared to 10.6% (153 of 1446) patients allocated to ambient air (HR 0.91, 95% CI 0.72-1.14; P = 0.41) ( Table 3) .
At 1 year, the rate of death from any cause was 4.2% vs. 4.9% in the two groups (oxygen/ambient air), respectively (HR 0.86, 95% CI 0.61-1.22; P = 0.41), the rate of rehospitalization with MI was 2.4% vs. 2.6%, respectively (HR 0.92, 95% CI 0.57-1.48; P = 0.73), the rate of rehospitalization with cardiogenic shock was 0.2% vs. 0.2%, respectively (HR 1.05, 95% CI 0.21-5.22; P = 0.95), and the rate of stent thrombosis was 0.6% vs. 0.5%, respectively (HR 1.27, 95% CI 0.46-3.51; P = 0.64) ( Table 3 ). The median duration of follow-up from the first included patient to 1-year follow-up of the last patient was 752 days (IQR 573-984) with a maximum of 1357 days. When the entire follow-up period was analysed, the incidence of the composite of all-cause death, rehospitalization with MI, cardiogenic shock, or stent thrombosis (MACE1) was 10.3% (140 of 1361) in patients allocated to oxygen compared to 11.5% (167 of 1446) in patients allocated to ambient air (HR 0.90, 95% CI 0.72-1.13; P = 0.38) ( Figure 3 and Table 3 ). The rate of death was 6.3% (86 of 1361) in patients allocated to oxygen vs. 6.9% (100 of 1446) in the patients allocated to ambient air (HR 0.94, 95% CI 0.70-1.25; P = 0.67) ( Table 3) .
The primary endpoint of the composite of all-cause death, rehospitalization with MI, cardiogenic shock, or stent thrombosis at 1 year was consistent across all relevant subgroups (Figure 4) .
No patients with STEMI were lost to follow-up for the primary endpoint.
In-hospital medication, trial and PCI procedures, and complications, were similar between the treatment groups (oxygen/ambient air) ( Table 2) , except for the rate of hypoxaemia (3.2% vs. 13.3%), the median oxygen saturation at the end of the treatment period (99% vs. 97%), the rate of unwillingness to continue participation in the trial (4.1% vs. 0.3%), the rate of clopidogrel use (7.9% vs. 10.7%), and the use of iv inotropes (2.6% vs. 4.0%), which were significantly different (P < 0.05).
Outcomes for patients not enrolled in the study
During the trial period, 7758 STEMI cases were reported at participating sites, and 2807 (36%) were enrolled in the DETO2X trial.
The remaining 4951 patients not enrolled in the trial were followed-up separately. The incidence of the composite of all-cause death, rehospitalization with MI, cardiogenic shock, or stent thrombosis at 1 year (MACE1) was 16.6% (821 of 4951). The incidence of the composite of all-cause death, rehospitalization with MI, cardiogenic shock, stent thrombosis, or target vessel revascularization at 1 year (MACE2) was 20.0% (988 of 4951). At 1 year, the rate of death from any cause was 13.4% (665 of 4951). The rate of rehospitalization with MI was 3.3% (165 of 4951), the rate of rehospitalization with cardiogenic shock was 0.3% (14 of 4951), and the rate of stent thrombosis was 0.7% (35 of 4951) ( Table 3) .
Discussion
In this pre-specified subgroup analysis of the DETO2X trial, an investigator-initiated, RRCT of supplemental oxygen or ambient air in patients with STEMI undergoing primary PCI, oxygen therapy did not reduce the rate of the composite of all-cause death, rehospitalization with MI, cardiogenic shock, or stent thrombosis at 1 year, at shortterm or the entire follow-up of the trial. Hypoxaemia occurred Take home figure The Kaplan-Meier curves for the composite of all-cause death, rehospitalization with myocardial infarction, cardiogenic shock, or stent thrombosis [major adverse cardiac event (MACE1)] up to 365 days. Enrolled ST-elevation myocardial infarction patients were randomized to either oxygen therapy at a moderate flowrate of 6 L/min for a median of 10.36 h or ambient air. The time from symptom onset to randomization and PCI was similar between the groups. The pre-specified primary composite endpoint of all-cause death, rehospitalization with myocardial infarction, cardiogenic shock, or stent thrombosis at 1 year occurred in 6.3% (86 of 1361) of patients allocated to oxygen compared to 7.5% (108 of 1446) allocated to ambient air (hazard ratio 0.85, 95% confidence interval 0.64-1.13; P = 0.27). Routine use of supplemental oxygen in normoxemic patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention did not significantly affect 1-year allcause death, rehospitalization with myocardial infarction, cardiogenic shock, or stent thrombosis. MACE, major adverse cardiac event.
substantially more often in the ambient-air group, but the primary outcome remained unaffected, most likely due to adequate oxygen supplementation in these cases. Equally important, we did not find any signs of increased risk by supplemental oxygen concerning the primary or secondary endpoints, or any relevant differences in procedures, medication or complications during hospital stay, within 1 year. The neutral outcome was consistent in relevant subgroups regardless of baseline clinical or angiographic characteristics.
As a result of a pragmatic study design, and strong commitment and compliance of the participating sites, we managed to enrol 36% of all eligible STEMI cases during the trial period. In less than 3 years, we were thereby able to enrol six times more STEMI patients than the largest contemporary oxygen trial. 6 Both beneficial and deleterious effects of oxygen therapy in STEMI patients have been proposed. 
21-23
Preclinical studies suggest a dose-dependent correlation between oxygen exposure and risk for myocardial injury 24 which also was reported in a post hoc analysis of a recent clinical study. 9 The results of our trial do not refute this potential risk. Our trial used moderate oxygen doses by open face mask avoiding excessive hyperoxaemia.
To demonstrate dose-dependent toxicity in a clinical trial by using doses much higher than applied in clinical practice, we perceived as unethical and impossible to perform. Further, in experimental studies, haemodynamic, histologic, or biochemical markers were analysed immediately or within short-term in a small number of subjects. [21] [22] [23] 25 In contrast, our study had long median follow-up. Haemodynamic changes might be transient with limited sustained long-term risk. Finally, discrepancies between preclinical studies 26 and smaller clinical trials with surrogate endpoints, [3] [4] [5] [6] and large clinical trials with hard outcomes are common.
General and conceptual limitations to the main study have been described in detail previously. 14 The results and conclusions of the present study are drawn from a pre-specified subgroup analysis without formal power and should be considered hypothesis generating. The lower-than expected event rate in the study population reduces power for evaluation of the primary endpoint, and we cannot completely rule out a small beneficial or unfavourable effect of oxygen treatment. However, the sample studied is large and the data quality very good concerning the primary objective. We pre-specified a primary composite endpoint with clinically important outcome variables relevant for STEMI patients undergoing PCI thus achieving a higher event rate in order to compensate for a limited sample size. Selected enrolment of STEMI patients is difficult in this setting as oxygen treatment usually is already started at first medical contact when the diagnosis of AMI still is uncertain. Our trial does not have sufficient power for conclusive subgroup analysis and future research needs to clarify this aspect. Although we recruited a large proportion of STEMI cases at participating sites, a comparison of the clinical characteristics and outcomes between the patients who underwent randomization and those who did not indicate that the two cohorts differed significantly. In general, patients not participating in the DETO2X trial were older and had a higher incidence of diabetes, MI, and previous PCI treatment. The incidence of death, rehospitalization with MI, cardiogenic shock, or stent thrombosis within 1 year occurred in 16.6% (821 of 4951) in non-randomized patients, compared to 6.9% (194 of 2807) in the study population. These differences most likely reflect the exclusion of frailer patients who were ineligible because they were hypoxaemic at presentation or unable for medical reasons to provide oral consent, aspects closely linked to poor prognosis. 27 Interestingly, other endpoints such as rehospitalization for repeat revascularization or stent thrombosis were very similar.
In the primary analysis of the DETO2X trial, we found that the broad population of normoxemic patients with suspected acute MI does not benefit from routine oxygen supplementation.
14 Experts have already called for a change in treatment paradigms towards a more restrictive use of supplemental oxygen, 28 and the oxygen saturation level below which oxygen treatment is recommended has recently been lowered to 90% in the 2017 European Society of Cardiology guidelines for STEMI patients. 29 We conclude that routine oxygen therapy in normoxemic patients with STEMI did not significantly reduce the rate of the composite of all-cause death, reinfarction, cardiogenic shock, or stent thrombosis at 1 year or longer follow-up. Thus, it appears reasonable and safe to withhold oxygen therapy in STEMI patients without hypoxaemia at baseline which goes well in line with recently changed guidelines. 29 Nevertheless, frequent monitoring remains mandatory as a subgroup of patients will develop hypoxaemia resulting in a need for immediate oxygen therapy.
